Search Results

Britannia selling its UK lab and testing business to a private UK-based acquiror for total enterprise value of up to £24.2 million (CAD$43.6 million) Initial consideration of £18.7 million (CAD$33.7 million) payable in cash on closing Additional consideration of up to £5.5 million (CAD$9.9 million) payable contingent on achieving certain EBITDA targets at March 2025 and December 2025. After the disposition Britannia will be debt free with assets that consist of significant cash reserves, and shares in Britannia Mining Solutions and Cosmetics Lab

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ongoing legal clashes in other parts of the world.

Calibre Scientific is pleased to announce the acquisitions of Microm UK Limited and Scopescreen, LLC, further solidifying its commitment to reproductive health and testing.

Patients in the U.K. with transfusion-dependent beta-thalassemia will have access to Vertex Pharmaceuticals’ gene editing therapy Casgevy, thanks to an agreement with the National Health Service on the price.

Aclarion, Inc. announced their initial payer coverage of Nociscan by AXA in London, UK in conjunction with The London Clinic, one of the UK’s largest and most renowned independent hospitals.

While approved by the Medicines and Healthcare products Regulatory Agency, the Alzheimer’s drug failed to win the backing of the U.K.’s National Institute for Health and Care Excellence, which said that its benefits were “too small to justify the cost.”

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025

SOLASCURE Ltd, a biotechnology company developing a novel treatment to transform chronic wound care, announced it has been selected for Innovate UK’s Global Incubator Programme in Houston, US.